Monday, 31 August 2026European Markets

ATENOR Stock Impressive Fall 17% So Far On Monday, Underperforms Market

Loading stream...

(VIANEWS) - Shares of ATENOR (BEL 20: ATEB.BR) slid by a staggering 17.74% to €32.00 at 11:09 EST on Monday, following the last session's upward trend. BEL 20 is rising 0.16% to €3,742.92, after two consecutive sessions in a row of gains. This seems, at the moment, a somewhat up trend exchanging session today.

About ATENOR

Atenor SA, a real estate development company, invests in large-scale real estate projects in Belgium, Luxembourg, the Netherlands, France, Germany, Portugal, Poland, Hungary, the United Kingdom, and Romania. The company develops real estate projects, such as offices and residential buildings. Atenor SA was founded in 1910 and is headquartered in La Hulpe, Belgium.

Earnings Per Share

As for profitability, ATENOR has a trailing twelve months EPS of €-0.13.

Volatility

ATENOR's last week, last month's, and last quarter's current intraday variation average was a negative 4.74%, a negative 2.28%, and a positive 1.50%.

ATENOR's highest amplitude of average volatility was 6.84% (last week), 2.97% (last month), and 1.50% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ATENOR's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for ATENOR is 2073 which is 17.37% below its average volume of 2509.

More news about ATENOR (ATEB.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com